MY169312A - An antiviral pharmaceutical composition - Google Patents

An antiviral pharmaceutical composition

Info

Publication number
MY169312A
MY169312A MYPI2013700109A MYPI2013700109A MY169312A MY 169312 A MY169312 A MY 169312A MY PI2013700109 A MYPI2013700109 A MY PI2013700109A MY PI2013700109 A MYPI2013700109 A MY PI2013700109A MY 169312 A MY169312 A MY 169312A
Authority
MY
Malaysia
Prior art keywords
pharmaceutical composition
dengue virus
antiviral pharmaceutical
present
virus infection
Prior art date
Application number
MYPI2013700109A
Inventor
Bin Abu Bakar Sazaly
Lam Yuen Suen Sherman
Tan Yee Koon Antony
Original Assignee
Herbitec M Sdn Bhd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Herbitec M Sdn Bhd filed Critical Herbitec M Sdn Bhd
Priority to MYPI2013700109A priority Critical patent/MY169312A/en
Priority to AU2014207946A priority patent/AU2014207946A1/en
Priority to PCT/MY2014/000004 priority patent/WO2014112861A1/en
Priority to SG11201505590TA priority patent/SG11201505590TA/en
Publication of MY169312A publication Critical patent/MY169312A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/539—Scutellaria (skullcap)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention relates to a pharmaceutical composition for use in reducing dengue virus count and treating or preventing dengue virus infection, comprising a therapeutically or prophylactically effective amount of an aqueous extract or bioactive compound derived from Scutellaria baicalensis. Use of this pharmaceutical composition as an antiviral drug or prophylaxis for dengue virus infection is also disclosed in the present invention.
MYPI2013700109A 2013-01-17 2013-01-17 An antiviral pharmaceutical composition MY169312A (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
MYPI2013700109A MY169312A (en) 2013-01-17 2013-01-17 An antiviral pharmaceutical composition
AU2014207946A AU2014207946A1 (en) 2013-01-17 2014-01-08 An antiviral pharmaceutical composition
PCT/MY2014/000004 WO2014112861A1 (en) 2013-01-17 2014-01-08 An antiviral pharmaceutical composition
SG11201505590TA SG11201505590TA (en) 2013-01-17 2014-01-08 An antiviral pharmaceutical composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MYPI2013700109A MY169312A (en) 2013-01-17 2013-01-17 An antiviral pharmaceutical composition

Publications (1)

Publication Number Publication Date
MY169312A true MY169312A (en) 2019-03-21

Family

ID=51209875

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2013700109A MY169312A (en) 2013-01-17 2013-01-17 An antiviral pharmaceutical composition

Country Status (4)

Country Link
AU (1) AU2014207946A1 (en)
MY (1) MY169312A (en)
SG (1) SG11201505590TA (en)
WO (1) WO2014112861A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106692127B (en) * 2016-12-12 2021-01-15 东莞广州中医药大学中医药数理工程研究院 Application of luteolin in preparation of medicine for preventing and treating dengue fever virus infection

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7605135B2 (en) * 2003-11-10 2009-10-20 The University Of Hong Kong Baicalin as a treatment for SARS infection
WO2009097512A1 (en) * 2008-02-01 2009-08-06 Innovative Drug Discovery Inc. Herbal pharmaceutical compositions to treat inflammation and inflammation associated conditions and diseases
MY151083A (en) * 2012-03-30 2014-04-04 Univ Malaya Antiviral composition against flavivirus

Also Published As

Publication number Publication date
WO2014112861A1 (en) 2014-07-24
SG11201505590TA (en) 2015-08-28
AU2014207946A1 (en) 2015-08-06

Similar Documents

Publication Publication Date Title
PH12015501648A1 (en) 2-aminopyrimidine derivatives for the treatment of viral infections
PH12014501738A1 (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
PH12015500983A1 (en) Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
MX347596B (en) Purine derivatives for the treatment of viral infections.
PH12015501156A1 (en) Pharmaceutical compositions
PE20151867A1 (en) SOLUBLE AND STABILIZED RESPIRATORY SYNCITIAL VIRUS (RSV) PREFUSION POLYPEPTIDES F
PH12015500724B1 (en) 1, 2, 4-triazine derivatives for the treatment of viral infections
IN2013MU01749A (en)
MX2015013809A (en) Macrocyclic deaza-purinones for the treatment of viral infections.
PH12015500713A1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
MX2022009352A (en) Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus.
WO2012093234A3 (en) Sulphated arabinogalactans, apiogalacturonans and sulphated heteroglycans for treating diseases caused by the influenza virus
MY171497A (en) Crystalline forms of dihydropyrimidine derivatives
GB2544439A (en) Antiviral composition
MX2021015441A (en) Crystalline forms of cabotegravir sodium.
MY169312A (en) An antiviral pharmaceutical composition
MX2016004961A (en) Methods and compositions for treatment of s. equi infection.
MY178049A (en) Composition with inhibitory effect on viral integrase activity
BR112017027082A2 (en) pharmaceutical composition, method for treating infection, extract, method for reducing viral load